2024
IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease
Serrano I, Ribeiro G, Santos R, Cruz J, Lanza F, dos Santos E, de Almeida M, de Souza Soares J, Luquetti A, Celedon P, Zanchin N, Santos F, dos Reis M. IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease. American Journal Of Tropical Medicine And Hygiene 2024, 110: 669-676. PMID: 38412539, PMCID: PMC10993828, DOI: 10.4269/ajtmh.23-0652.Peer-Reviewed Original ResearchClinical presentationChronic CDClinical formsSpectrum of clinical presentationsIg profilesSevere cardiac involvementChagas diseaseChronic Chagas diseaseSerum samplesDevelopment of tissue damageHost immune responseCross-sectional studyCardiac involvementIgG3 levelsImmunopathogenic mechanismsDisease progressionProgression of CDRecombinant chimeric proteinImmune responseIgG isotypeIgG3 isotypesTotal IgGMC groupSC groupDisease pathogenesis
2022
Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients
Ramchandren S, Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Mantecon M, Ling L, Zhu Y, Karcher K, Sun H. Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology 2022, 99: s35-s37. DOI: 10.1212/01.wnl.0000903304.73134.e3.Peer-Reviewed Original ResearchPhase 2 studyMyasthenia gravis patientsClinical improvementGravis patientsMonoclonal antibodiesAnti-AChR autoantibodiesMuSK-positive patientsMyasthenia Gravis ActivitiesDaily living scoreSerum total IgGSerum IgG levelsMG-ADL scoreNeonatal Fc receptorGMG patientsClinical responseDose armLiving scorePathogenic autoantibodiesPositive patientsIgG levelsPathogenic antibodiesIgG autoantibodiesPharmacodynamic effectsSerum IgGTotal IgG
2017
Functional Analysis Reveals Geographical Variation in Inhibitory Immune Responses Against a Polymorphic Malaria Antigen
Bei AK, Ahouidi AD, Dvorin JD, Miura K, Diouf A, Ndiaye D, Premji Z, Diakite M, Mboup S, Long CA, Duraisingh MT. Functional Analysis Reveals Geographical Variation in Inhibitory Immune Responses Against a Polymorphic Malaria Antigen. The Journal Of Infectious Diseases 2017, 216: 267-275. PMID: 28605544, PMCID: PMC5853457, DOI: 10.1093/infdis/jix280.Peer-Reviewed Original ResearchConceptsInhibitory immune responsesVaccine candidate antigenImmune responseTransgenic parasite linesMalaria-endemic regionsReticulocyte-binding protein homologuesMalaria vaccine candidateParasite linesWild-type controlsTotal IgGHumoral responseMalaria antigensAntibody responseVaccine candidatesCandidate antigensMalaria endemicityGrowth inhibition assaysInvasion ligandsAntigenic specificityImmunogenic domainsSpecific antibodiesEndemic sitesAntigenStandardized toolsInhibition assays
2015
Immune response to Propionibacterium acnes in patients with sarcoidosis – in vivo and in vitro
Schupp J, Tchaptchet S, Lützen N, Engelhard P, Müller-Quernheim J, Freudenberg M, Prasse A. Immune response to Propionibacterium acnes in patients with sarcoidosis – in vivo and in vitro. BMC Pulmonary Medicine 2015, 15: 75. PMID: 26204953, PMCID: PMC4513400, DOI: 10.1186/s12890-015-0070-7.Peer-Reviewed Original ResearchConceptsHeat-killed P. acnesSarcoid patientsP. acnesBAL cellsBAL fluidTotal IgGImmune responseHealthy volunteersPathogenesis of sarcoidosisSpecific antibodiesGM-CSF productionIgA titresIgA levelsLymph nodesInflammatory cytokinesGranuloma formationMore TNFSarcoidosisPatientsPropionibacterium acnesAcneGM-CSFElevated levelsAntibodiesIgG
2001
Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis
Goluszko E, Hjelmström P, Deng C, Poussin M, Ruddle N, Christadoss P. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis. Journal Of Neuroimmunology 2001, 113: 109-118. PMID: 11137582, DOI: 10.1016/s0165-5728(00)00420-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDAutoantibodiesB7-2 AntigenGene ExpressionImmunodominant EpitopesImmunoglobulin GImmunoglobulin MLymphotoxin-alphaMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutMyasthenia Gravis, Autoimmune, ExperimentalReceptors, CholinergicReceptors, Tumor Necrosis FactorSpleenConceptsExperimental autoimmune myasthenia gravisClinical experimental autoimmune myasthenia gravisAutoimmune myasthenia gravisMyasthenia gravisMean titersPrimary humoral immune responseAlpha-deficient miceAnti-AChR antibodiesHumoral immune responseLower mean titersC57BL/6 miceImmunized miceTotal IgGDeficient miceIgG isotypeImmune responseAcetylcholine receptorsPartial preventionGravisMiceComplete preventionTitersLtPreventionPathogenesis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply